June 19th 2025
Median overall survival was 5 months longer in patients with small cell lung cancer (SCLC) who received tarlatamab instead of chemotherapy after progression following platinum-based chemotherapy.
Radiation Oncology’s Role in the Next Chapter of Payment Reform
Amy Ellis: There Was a Big Shift to Telemedicine in Cancer Care Delivery